Spero Therapeutics Inc
NASDAQ:SPRO
Cash Flow Statement
Cash Flow Statement
Spero Therapeutics Inc
Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||||||||||||||||||||||
Net Income |
(39)
|
(32)
|
(34)
|
(40)
|
(44)
|
(44)
|
(45)
|
(42)
|
(36)
|
(39)
|
(47)
|
(61)
|
(79)
|
(83)
|
(85)
|
(78)
|
(74)
|
(76)
|
(79)
|
(90)
|
(103)
|
(113)
|
(102)
|
(46)
|
(27)
|
(10)
|
(2)
|
23
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
Other Non-Cash Items |
3
|
(2)
|
(1)
|
(0)
|
2
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
5
|
4
|
5
|
5
|
6
|
8
|
9
|
12
|
16
|
17
|
18
|
16
|
12
|
10
|
15
|
14
|
|
Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
2
|
|
Change in Working Capital |
(0)
|
2
|
(1)
|
0
|
(2)
|
(3)
|
3
|
(1)
|
(6)
|
(6)
|
(4)
|
7
|
11
|
3
|
(7)
|
(13)
|
(10)
|
(2)
|
16
|
13
|
10
|
12
|
4
|
22
|
22
|
12
|
16
|
(70)
|
|
Cash from Operating Activities |
(36)
N/A
|
(32)
+12%
|
(36)
-13%
|
(39)
-10%
|
(44)
-13%
|
(44)
+1%
|
(39)
+11%
|
(40)
-2%
|
(39)
+3%
|
(42)
-9%
|
(46)
-10%
|
(50)
-8%
|
(62)
-25%
|
(75)
-21%
|
(87)
-15%
|
(86)
+1%
|
(78)
+9%
|
(70)
+11%
|
(53)
+23%
|
(64)
-21%
|
(77)
-20%
|
(84)
-8%
|
(80)
+5%
|
(8)
+90%
|
8
N/A
|
12
+59%
|
29
+139%
|
(33)
N/A
|
|
Investing Cash Flow | |||||||||||||||||||||||||||||
Capital Expenditures |
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(2)
|
(3)
|
(3)
|
(3)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Items |
0
|
0
|
0
|
0
|
(23)
|
(18)
|
(90)
|
(81)
|
(33)
|
(13)
|
44
|
30
|
33
|
27
|
46
|
11
|
(14)
|
(22)
|
(9)
|
8
|
(11)
|
28
|
11
|
34
|
50
|
(0)
|
0
|
0
|
|
Cash from Investing Activities |
(1)
N/A
|
(0)
+43%
|
(0)
+45%
|
(0)
+88%
|
(23)
-76 100%
|
(18)
+22%
|
(90)
-407%
|
(83)
+8%
|
(36)
+57%
|
(16)
+56%
|
41
N/A
|
30
-28%
|
33
+11%
|
26
-20%
|
46
+76%
|
10
-77%
|
(14)
N/A
|
(22)
-53%
|
(9)
+60%
|
8
N/A
|
(11)
N/A
|
28
N/A
|
11
-62%
|
34
+221%
|
50
+48%
|
(0)
N/A
|
0
N/A
|
0
N/A
|
|
Financing Cash Flow | |||||||||||||||||||||||||||||
Net Issuance of Common Stock |
77
|
0
|
95
|
121
|
121
|
121
|
148
|
71
|
72
|
81
|
11
|
16
|
45
|
44
|
121
|
132
|
106
|
98
|
51
|
37
|
36
|
37
|
13
|
25
|
21
|
20
|
14
|
0
|
|
Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(54)
|
(54)
|
(54)
|
0
|
0
|
0
|
0
|
|
Other |
0
|
42
|
(2)
|
(5)
|
0
|
(47)
|
(4)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
47
|
47
|
47
|
48
|
0
|
0
|
0
|
0
|
0
|
|
Cash from Financing Activities |
77
N/A
|
50
-35%
|
50
-1%
|
116
+133%
|
73
-37%
|
74
+1%
|
144
+95%
|
70
-52%
|
71
+2%
|
80
+13%
|
10
-87%
|
16
+56%
|
45
+177%
|
43
-4%
|
120
+179%
|
131
+9%
|
105
-20%
|
98
-7%
|
50
-49%
|
84
+69%
|
84
-1%
|
30
-64%
|
7
-78%
|
(30)
N/A
|
(33)
-13%
|
20
N/A
|
14
-29%
|
0
-98%
|
|
Change in Cash | |||||||||||||||||||||||||||||
Net Change in Cash |
41
N/A
|
18
-55%
|
14
-23%
|
77
+446%
|
6
-92%
|
12
+101%
|
15
+22%
|
(53)
N/A
|
(3)
+94%
|
22
N/A
|
5
-77%
|
(4)
N/A
|
15
N/A
|
(6)
N/A
|
80
N/A
|
55
-30%
|
13
-77%
|
6
-51%
|
(12)
N/A
|
27
N/A
|
(5)
N/A
|
(26)
-431%
|
(62)
-139%
|
(3)
+94%
|
24
N/A
|
32
+34%
|
43
+34%
|
(33)
N/A
|
|
Free Cash Flow | |||||||||||||||||||||||||||||
Free Cash Flow |
(36)
N/A
|
(32)
+11%
|
(36)
-12%
|
(39)
-9%
|
(44)
-13%
|
(44)
+1%
|
(39)
+11%
|
(42)
-8%
|
(41)
+2%
|
(45)
-9%
|
(49)
-9%
|
(50)
-3%
|
(63)
-25%
|
(75)
-20%
|
(87)
-15%
|
(86)
+1%
|
(78)
+9%
|
(70)
+11%
|
(53)
+23%
|
(64)
-21%
|
(77)
-20%
|
(84)
-8%
|
(80)
+5%
|
(8)
+90%
|
8
N/A
|
12
+59%
|
29
+139%
|
(33)
N/A
|